Daniel Nadler, the 42-year-old CEO and cofounder of OpenEvidence, is now worth $7.6 billion as his AI search tool surges in popularity among U.S. doctors.
Officials from the US Department of Health and Human Services, which funded the controversial study, say that it will proceed ...
At ACR Convergence 2025, Cassandra Calabrese, DO, and I were invited to deliver a joint concurrent session with the ...
A consumer pricing framework for 'Cheapest Compounded Semaglutide,' 'Cheapest Compounded Semaglutide Online,' and 'Cheapest ...
9h
Study shows importance of conservative evaluation approach to unexplained unintentional weight loss
Researchers at University Hospitals Cleveland Medical Center have completed a study aimed at improving how physicians ...
Brazilian magnetic capsules may expand access to gastrointestinal motility testing without radiation, but clinical validation ...
Following the release of ChatGPT Health, due to an increased interest in AI-driven medical guidance, MNT discusses the role ...
When we think of a clinical trial we often imagine the global breakthroughs the headlines announcing a new cure or a revolutionary vaccine however the true work happens in the trenches at the clinical ...
Joseph Tucker, an infectious disease doctor, asks every patient what they’re grateful for. Sometimes, their responses ...
Nearly one-third of patients who responded to a survey did not understand common skin cancer terms frequently used by ...
People with psychotic disorders are developing delusions tied to AI use. While not an official diagnosis yet, AI psychosis is ...
Thrive Capital and DST Global led the investment. It values OpenEvidence at $12 billion, more than ten times what the company was worth after its first funding round last February. The startup has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback